Green light for Sanofi, Regeneron’s Kevzara
Sanofi and Regeneron’s Kevzara has been cleared in the US to treat moderately to severely active rheumatoid arthritis (RA) in adult patients.
Read More
Tag: IL-6R
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
